These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27083246)

  • 1. Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.
    Samson P; Puri V; Robinson C; Lockhart C; Carpenter D; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    Ann Thorac Surg; 2016 Jun; 101(6):2102-11. PubMed ID: 27083246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
    Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
    J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival.
    Crabtree TD; Yacoub WN; Puri V; Azar R; Zoole JB; Patterson GA; Krupnick AS; Kreisel D; Meyers BF
    Ann Thorac Surg; 2011 May; 91(5):1509-15; discussion 1515-6. PubMed ID: 21435632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.
    Stiles BM; Mirza F; Coppolino A; Port JL; Lee PC; Paul S; Altorki NK
    Ann Thorac Surg; 2011 Aug; 92(2):491-6; discussion 496-8. PubMed ID: 21704291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database.
    Crabtree TD; Kosinski AS; Puri V; Burfeind W; Bharat A; Patterson GA; Hofstetter W; Meyers BF
    Ann Thorac Surg; 2013 Aug; 96(2):382-90. PubMed ID: 23731608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemoradiation Versus Upfront Esophagectomy in Clinical Stage II and III Esophageal Squamous Cell Carcinoma.
    Hsu PK; Chen HS; Liu CC; Wu SC
    Ann Surg Oncol; 2019 Feb; 26(2):506-513. PubMed ID: 30430325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
    Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
    Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.
    Barbetta A; Schlottmann F; Nobel T; Sewell DB; Hsu M; Tan KS; Gerdes H; Shah P; Bains MS; Bott M; Isbell JM; Jones DR; Molena D
    Ann Thorac Surg; 2018 Jul; 106(1):172-177. PubMed ID: 29627387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?
    Perez Holguin RA; Olecki EJ; Stahl KA; Wong WG; Vining CC; Dixon MEB; Peng JS
    J Gastrointest Surg; 2022 Oct; 26(10):2050-2060. PubMed ID: 36042124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Therapy Vs Upfront Surgery for Clinical T2N0 Esophageal Cancer: A Systematic Review.
    Kidane B; Korst RJ; Weksler B; Farrell A; Darling GE; Martin LW; Reddy R; Sarkaria IS
    Ann Thorac Surg; 2019 Sep; 108(3):935-944. PubMed ID: 31077657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging accuracy in patients with clinical T2N0 gastric cancer: Implications for treatment sequencing.
    Baril JA; Ruedinger BM; Nguyen TK; Bilimoria KY; Ceppa EP; Maatman TK; Roch AM; Schmidt CM; Turk A; Yang AD; House MG; Ellis RJ
    Surgery; 2024 Oct; ():. PubMed ID: 39358121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Pathologic Upstaging in cT1b Esophageal Cancer: Should We Consider Neoadjuvant Therapy?
    Mann DR; Engelhardt KE; Gibney BC; Batten ME; Klipsch EC; Mukherjee R; Bostock IC
    J Surg Res; 2024 Mar; 295():61-69. PubMed ID: 37992454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.